Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Antibe Therapeutics Inc. stock logo
ATE
Antibe Therapeutics
C$0.00
C$0.15
C$1.23
C$15.64M0.19135,475 shs167,044 shs
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
C$0.11
+5.0%
C$0.09
C$0.08
C$0.32
C$25.67M2.996,444 shs4,500 shs
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
$10.70
$10.70
$3.95
$11.35
$292.42M2.38327,575 shs54 shs
Resverlogix Corp. stock logo
RVX
Resverlogix
C$0.05
C$0.04
C$0.04
C$0.10
C$8.91M0.7156,344 shs9,000 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Antibe Therapeutics Inc. stock logo
ATE
Antibe Therapeutics
0.00%0.00%0.00%0.00%0.00%
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
+5.00%+5.00%+23.53%+5.00%-58.82%
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
0.00%0.00%0.00%0.00%0.00%
Resverlogix Corp. stock logo
RVX
Resverlogix
-10.00%0.00%+12.50%-10.00%-25.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Antibe Therapeutics Inc. stock logo
ATE
Antibe Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
N/AN/AN/AN/AN/AN/AN/AN/A
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
N/AN/AN/AN/AN/AN/AN/AN/A
Resverlogix Corp. stock logo
RVX
Resverlogix
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Antibe Therapeutics Inc. stock logo
ATE
Antibe Therapeutics
0.00
N/AN/AN/A
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
0.00
N/AN/AN/A
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
0.00
N/AN/AN/A
Resverlogix Corp. stock logo
RVX
Resverlogix
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Antibe Therapeutics Inc. stock logo
ATE
Antibe Therapeutics
C$9.71M0.00N/A0.61C$0.49 per share0.00
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
C$724.40K35.44C$0.00 per share39.00C$0.02 per share4.28
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
$937.80M0.31$1.97 per share5.43$3.40 per share3.15
Resverlogix Corp. stock logo
RVX
Resverlogix
N/AN/AC$0.00 per share132.50C($0.23) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Antibe Therapeutics Inc. stock logo
ATE
Antibe Therapeutics
-C$18.24M-C$0.35N/AN/AN/AN/A-52.72%-19.13%N/A
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
-C$12.74M-C$0.06N/AN/A-1,758.62%-185.21%-39.22%N/A
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
$48.50M$1.776.05N/A5.17%66.00%15.67%N/A
Resverlogix Corp. stock logo
RVX
Resverlogix
-C$2.81M-C$0.02N/AN/AN/A6.06%-34.90%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Antibe Therapeutics Inc. stock logo
ATE
Antibe Therapeutics
C$0.05N/AN/AN/A N/A
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
N/A4.45%N/AN/AN/A
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
N/AN/AN/AN/AN/A
Resverlogix Corp. stock logo
RVX
Resverlogix
N/A7.02%N/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Antibe Therapeutics Inc. stock logo
ATE
Antibe Therapeutics
0.29
10.06
9.58
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
187.90
5.63
1.71
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
0.75
2.05
0.95
Resverlogix Corp. stock logo
RVX
Resverlogix
-10.95
0.13
0.04

Institutional Ownership

CompanyInstitutional Ownership
Antibe Therapeutics Inc. stock logo
ATE
Antibe Therapeutics
N/A
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
0.21%
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
54.10%
Resverlogix Corp. stock logo
RVX
Resverlogix
N/A

Insider Ownership

CompanyInsider Ownership
Antibe Therapeutics Inc. stock logo
ATE
Antibe Therapeutics
7.94%
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
28.06%
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
10.95%
Resverlogix Corp. stock logo
RVX
Resverlogix
42.66%
CompanyEmployeesShares OutstandingFree FloatOptionable
Antibe Therapeutics Inc. stock logo
ATE
Antibe Therapeutics
1153.01 millionN/ANot Optionable
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
20244.51 millionN/ANot Optionable
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
1,10027.33 million24.34 millionOptionable
Resverlogix Corp. stock logo
RVX
Resverlogix
19197.94 millionN/ANot Optionable

Recent News About These Companies

Resverlogix Corp. (RVXCF)
Closing Bell: Resverlogix Corp up on Tuesday (RVX)
Closing Bell: Resverlogix Corp flat on Wednesday (RVX)
Resverlogix Corp. (RVX.TO)
Resverlogix Announces Change to Its Board of Directors
Closing Bell: Resverlogix Corp flat on Tuesday (RVX)
Resverlogix Corp. (RVX) Earnings Dates & Reports
Resverlogix Corp RVXCF
Resverlogix Corp RVX

Media Sentiment Over Time

Top Headlines

View All Headlines
Antibe Therapeutics stock logo

Antibe Therapeutics TSE:ATE

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

Burcon NutraScience stock logo

Burcon NutraScience TSE:BU

C$0.10 +0.01 (+5.00%)
As of 05/12/2025 01:02 PM Eastern

Burcon NutraScience Corporation, together with its subsidiaries, develops plant proteins and ingredients for use in the food and beverage industries in Canada. The company offers Peazazz and Peazac, a pea protein for use in dairy alternatives, ready-to-drink beverages, dry blended beverages, bars, baked goods, and meat substitute products. It provides Puratein, a canola protein isolate for use in meat alternatives, such as burgers, sausages, and nutrition bars; Supertein, a canola protein that is a light-colored powder for use in non-dairy frozen desserts, egg alternative, plant-based marshmallows and ready-to-mix beverages, whipped toppings, and plant-based bars; and Nutratein, a canola protein comprising a mixture of globulin and albumin proteins for use in meat and egg alternatives, and other plant-based functional foods. In addition, the company offers Nutratein-PS, a blend of Peazazz pea protein and Supertein canola protein; Nutratein-TZ, a blend of Peazac pea protein and Puratein canola protein; and CLARISOY, a soy protein for use in sports nutrition beverages, citrus-based drinks, fruit-flavored beverages, lemonades, powdered beverage mixes, and non-beverage plant-based products. The company was formerly known as Burcon Capital Corp. and changed its name to Burcon NutraScience Corporation in October 1999. The company was incorporated in 1998 and is headquartered in Vancouver, Canada.

Huttig Building Products stock logo

Huttig Building Products NASDAQ:HBP

Huttig Building Products, Inc., together with its subsidiaries, distributes millwork, building materials, and wood products for new residential construction, in-home improvement, remodeling, and repair works in the United States. The company offers various millwork products, including exterior and interior doors, pre-hung and factory finished door units, windows, patio doors, mouldings, frames, stair parts, and columns under the Therma-Tru, Masonite, Woodgrain, HB&G, Simpson Door, Final Frame, BrasPine, Arauco, Windsor Windows, and Rogue Valley Door brands. It also provides general building products, such as fasteners and connectors, roofing, siding, insulation, flashing, housewrap, decking, railings, and other miscellaneous building products under the Huttig-Grip, Louisiana-Pacific, Simpson Strong-Tie, TimberTech, AZEK, RDI, GAF Roofing, Maibec, Knauf, GCP Technologies, Fiberon, Alpha Protech, MFM, Lomanco, and Fortifiber brands. In addition, the company offers wood products comprising engineered wood products used in floor systems, wood panels, and lumber; and value-added services, such as floor system take-offs, cut-to-length packages and just-in-time, and cross-dock delivery under the Louisiana-Pacific and Rosboro brands. It markets and sells its products through a network of 25 wholesale distribution centers serving approximately 41 states to building materials dealers, national buying groups, home centers, and industrial users comprising makers of manufactured homes. Huttig Building Products, Inc. was founded in 1865 and is headquartered in St. Louis, Missouri.

Resverlogix stock logo

Resverlogix TSE:RVX

C$0.04 0.00 (0.00%)
As of 05/12/2025 03:58 PM Eastern

Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.